Literature DB >> 1997044

Disposition of morphine-6-glucuronide and morphine in healthy volunteers.

M H Hanna1, S J Peat, A A Knibb, C Fung.   

Abstract

The pharmacokinetics and subjective side effects of i.v. morphine sulphate 120 micrograms kg-1 and morphine-6-glucuronide (M6G) 30 micrograms kg-1 were determined in six healthy volunteers, using a placebo-controlled, single-blind randomized crossover design. Five of these volunteers underwent an additional (non-randomized) study of M6G 60 micrograms kg-1. Subjective side effects were similar following both drugs, but of shorter duration following M6G. Morphine was not detected after administration of M6G. For M6G 30 micrograms kg-1 the mean (SD) volume of distribution, elimination half-life and clearance were 29.38 (18.36) litre, 2.05 (1.2) h and 187.81 (37.41) litre h-1, respectively. These values were not significantly different from those obtained for M6G 60 micrograms kg-1. In all subjects the volumes of distribution and clearances were significantly smaller for M6G than for morphine, but the elimination half-lives were similar.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1997044     DOI: 10.1093/bja/66.1.103

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  18 in total

1.  Analgesic and immunomodulatory effects of codeine and codeine 6-glucuronide.

Authors:  V Srinivasan; D Wielbo; J Simpkins; J Karlix; K Sloan; I Tebbett
Journal:  Pharm Res       Date:  1996-02       Impact factor: 4.200

2.  ABCC3 and OCT1 genotypes influence pharmacokinetics of morphine in children.

Authors:  Raja Venkatasubramanian; Tsuyoshi Fukuda; Jing Niu; Tomoyuki Mizuno; Vidya Chidambaran; Alexander A Vinks; Senthilkumar Sadhasivam
Journal:  Pharmacogenomics       Date:  2014-07       Impact factor: 2.533

3.  Blood-brain distribution of morphine-6-glucuronide in sheep.

Authors:  H H Villesen; D J R Foster; R N Upton; L L Christrup; A A Somogyi; A Martinez; C Grant
Journal:  Br J Pharmacol       Date:  2006-10-03       Impact factor: 8.739

4.  Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis.

Authors:  B C Ferslew; C K Johnston; E Tsakalozou; A S Bridges; M F Paine; W Jia; P W Stewart; A S Barritt; K L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2015-03-15       Impact factor: 6.875

Review 5.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

6.  Morphine metabolite pharmacokinetics during venoarterial extra corporeal membrane oxygenation in neonates.

Authors:  Jeroen W B Peters; Brian J Anderson; Sinno H P Simons; Donald R A Uges; Dick Tibboel
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 7.  Pharmacokinetics of opioids in renal dysfunction.

Authors:  G Davies; C Kingswood; M Street
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

Review 8.  Morphine-6-glucuronide: an analgesic of the future?

Authors:  J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

9.  Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations.

Authors:  J Hasselström; J Säwe
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

10.  Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine.

Authors:  Ingolf Meineke; Stefan Freudenthaler; Ute Hofmann; Elke Schaeffeler; Gerd Mikus; Matthias Schwab; Hilmar W Prange; Christoph H Gleiter; J Brockmöller
Journal:  Br J Clin Pharmacol       Date:  2002-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.